Recent research published in the American Journal of Preventive Medicine provides updated evidence on nicotine pouch use among adults in the United States, offering new insights into usage patterns, population trends, and potential regulatory considerations. The study, Nicotine Pouch Use Among U.S. Adults in 2023 and 2024, examines nationally representative data to assess how use…
At EVO NXT 2026, the Global Institute for Novel Nicotine hosted a panel session exploring the factors influencing consumer adoption of new nicotine products, focusing on innovation, accessibility, and regulatory context. The session was moderated by Marc Reisner and featured contributions from Waqas Khan, Vincent Reid, and John Dunne, offering perspectives from manufacturing, distribution, and…
At EVO NXT 2026, the Global Institute for Novel Nicotine opened its programme with a panel session examining the latest scientific evidence, regulatory frameworks, and public health considerations surrounding tobacco harm reduction. The session was moderated by Philipp Markl and featured contributions from Dr Sydney Hiller, Sairah Salim-Sartoni, and John Dunne, bringing together perspectives from…
New U.S. evidence highlights patterns relevant to harm reduction policy As nicotine pouches (ONPs) continue to expand in the United States, understanding how adult smokers engage with these products is becoming increasingly important for evidence-based regulation. A recent peer-reviewed study using nationally representative data from the Population Assessment of Tobacco and Health (PATH) Study provides…
Across the European Union, tobacco control policy has historically focused on reducing smoking through restrictions, taxation, and public health campaigns. These measures have contributed to steady declines in smoking prevalence over time. However, the pace of change has varied across Member States, and smoking remains a significant public health concern. Within this broader context, Sweden…
Across the European Union, tobacco control policy has long focused on reducing smoking prevalence through a combination of regulatory restrictions, public health campaigns, and excise taxation. These approaches have contributed to meaningful progress over time. However, smoking remains a leading cause of preventable disease, and reducing its impact continues to be a central objective of…
Public health policy often develops through long institutional processes. Regulations are debated, negotiated, and revised through multiple stages of consultation and political review. This is particularly true in the European Union, where legislative frameworks such as the Tobacco Products Directive (TPD) and the Tobacco Excise Directive (TED) shape tobacco and nicotine policy across all Member…
Debates around nicotine policy often focus narrowly on dependence and youth protection. Far less frequently examined, but increasingly discussed in scientific and policy literature, is nicotine’s relationship with cognition and mental health. Emerging research suggests that nicotine may have measurable short-term effects on attention, working memory, and executive function. At the same time, long-standing concerns…
Public debate around tobacco harm reduction (THR) is increasingly shaped not only by science, but by how that science is communicated. As non-combustible nicotine products expand across global markets, the gap between evidence and public understanding has become a central policy challenge. Miscommunication, oversimplification, and emotive framing risk distorting regulatory discussions at precisely the moment…
Debates around tobacco harm reduction are increasingly shaped not only by emerging products and regulatory decisions, but by how science itself is communicated. A recent commentary on misinformation and “clickbait science” in the tobacco harm reduction space highlights a growing concern: that exaggerated claims, selective interpretation of findings, and sensational headlines can distort both public…